Related references
Note: Only part of the references are listed.Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma
David A. Braun et al.
NATURE MEDICINE (2020)
Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition
Barzin Y. Nabet et al.
CELL (2020)
Array programming with NumPy
Charles R. Harris et al.
NATURE (2020)
Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade
Qu Zhang et al.
CANCER DISCOVERY (2020)
A benchmark of batch-effect correction methods for single-cell RNA sequencing data
Hoa Thi Nhu Tran et al.
GENOME BIOLOGY (2020)
Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy (vol 28, pg 2707, 2017)
C. E. McCoach et al.
ANNALS OF ONCOLOGY (2019)
First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers
Neal Ready et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?
Meihua Wang et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Tony S. K. Mok et al.
LANCET (2019)
Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC
Scott J. Antonia et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Prediction of response to anti-PD-1 therapy in patients with non-small-cell lung cancer by electronic nose analysis of exhaled breath
R. de Vries et al.
ANNALS OF ONCOLOGY (2019)
Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer
Valsamo Anagnostou et al.
CANCER RESEARCH (2019)
Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) Blockade
Juan C. Osorio et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer
Matthew D. Hellmann et al.
CANCER CELL (2018)
Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA
Sarah B. Goldberg et al.
CLINICAL CANCER RESEARCH (2018)
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
Diana Miao et al.
SCIENCE (2018)
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors
Diana Miao et al.
NATURE GENETICS (2018)
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Lesley Seymour et al.
LANCET ONCOLOGY (2017)
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance
Whijae Roh et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
RNA sequencing-based cell proliferation analysis across 19 cancers identifies a subset of proliferation-informative cancers with a common survival signature
Ryne C. Ramaker et al.
ONCOTARGET (2017)
Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials A Meta-analysis
Gideon M. Blumenthal et al.
JAMA ONCOLOGY (2017)
1070PADAPTATION OF THE IMMUNE RELATED RESPONSE CRITERIA: IRRECIST
O. Bohnsack et al.
ANNALS OF ONCOLOGY (2017)
Safety and antitumour activity of durvalumab plus tremelimumab in non-small-cell lung cancer: a multicentre, phase 1b study
Scott Antonia et al.
LANCET ONCOLOGY (2016)
Chromosomal Instability Selects Gene Copy-Number Variants Encoding Core Regulators of Proliferation in ER+ Breast Cancer
David Endesfelder et al.
CANCER RESEARCH (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements
Mizuki Nishino et al.
CLINICAL CANCER RESEARCH (2013)
A general method to derive robust organ-specific gene expression-based differentiation indices: application to thyroid cancer diagnostic
G. Tomas et al.
ONCOGENE (2012)
Most Random Gene Expression Signatures Are Significantly Associated with Breast Cancer Outcome
David Venet et al.
PLOS COMPUTATIONAL BIOLOGY (2011)
Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases
Anna Maria Di Giacomo et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues
XJ Ge et al.
GENOMICS (2005)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
